Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an update.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has proposed the appointment of 35-year-old Liu Hongkang, currently an investment manager at SDIC Venture Capital Management, as a non-executive director, subject to approval by shareholders at an upcoming extraordinary general meeting. Liu, who holds a doctorate in biophysics and a bachelor’s in biotechnology from Huazhong University of Science and Technology, has no prior roles within Biocytogen or other listed companies and no disclosed shareholding or related-party ties, and will serve without remuneration; if approved, he will also join the audit committee and strategy development committee, a move that signals the company’s intent to strengthen its governance and strategic oversight by adding capital markets and scientific expertise to its board.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$48.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a PRC-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 2315. The firm operates in the pharmaceutical and life sciences industry, focusing on drug discovery and related biotechnological research, and is governed by a multi-tier board structure comprising executive, non-executive, independent non-executive and employee directors.
Average Trading Volume: 1,465,713
Technical Sentiment Signal: Hold
Current Market Cap: HK$16.99B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.